ThinkEquity initiated coverage on shares of BioVie (NASDAQ:BIVI – Free Report) in a report published on Monday, Benzinga reports. The firm issued a buy rating and a $3.00 price objective on the stock.
BioVie Stock Performance
BioVie stock opened at $0.42 on Monday. BioVie has a fifty-two week low of $0.40 and a fifty-two week high of $5.82. The stock has a market cap of $25.48 million, a PE ratio of -0.44 and a beta of 0.74. The firm’s 50-day simple moving average is $0.47 and its 200 day simple moving average is $0.79.
BioVie (NASDAQ:BIVI – Get Free Report) last released its quarterly earnings results on Tuesday, May 14th. The company reported ($0.20) earnings per share for the quarter.
Institutional Inflows and Outflows
BioVie Company Profile
BioVie Inc, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of chronic debilitating conditions in the United States. Its products pipeline includes BIV201, which completed Phase IIa clinical trial for the treatment of ascites caused due to chronic liver cirrhosis; and NE3107, a potentially selective inhibitor of inflammatory extracellular single-regulated kinase, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease, as well as Phase 2 clinical trial for the treatment of Parkinson's disease.
Recommended Stories
- Five stocks we like better than BioVie
- Learn Technical Analysis Skills to Master the Stock Market
- These Top 3 Banks Raise Dividends After Passing Fed Stress Test
- What Does a Gap Up Mean in Stocks? How to Play the Gap
- Hitch a Ride with Lyft Stock for Double-Digit Gains in 2nd Half
- Investing in Construction Stocks
- Eli Lilly Stock Up: GLP-1 Zepbound Targets Sleep Apnea Market
Receive News & Ratings for BioVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioVie and related companies with MarketBeat.com's FREE daily email newsletter.